Advancing mAbs to Achieve a Drug-free Sustained HIV Virologic Remission (U01 Clinical Trial Required)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement is to solicit applications to rapidly implement clinical trials focused on advancing the early clinical development of native and/or engineered monoclonal antibodies (mAbs) to achieve a drug-free sustained virologic remission in HIV infected individuals.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): October 10, 2018, October 9, 2019
  • AIDS Application Due Date(s): October 10, 2018, October 9, 2019

RFA-AI-18-022 Expiration Date October 10, 2019  

Agency Website

Eligibility Requirements

U.S.-based institutions must receive primary awards through this FOA. Foreign collaborators are permitted if scientifically justified and feasible given the proposed study design, but the clinical site(s) must be located in the United States.

Amount Description

NIAID intends to commit $3M in FY 19 to fund 2-3 awards and $3M in FY20 to fund 2-3 awards.

Funding Type





Medical - Clinical Science

External Deadline

October 9, 2019